Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness

Clicks: 90
ID: 266828
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1 of 4 articles by views in Journal of the Canadian Association of Gastroenterology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Increasing remission rates were observed over the first six months of VDZ treatment. One-fifth of patients not in remission post-induction achieved remission by six months of continued therapy. Mucosal healing was associated with higher rates of one-year steroid-free remission and VDZ treatment cont …
Reference Key
p2020journalulcerative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zezos P;Kabakchiev B;Weizman AV;Nguyen GC;Narula N;Croitoru K;Steinhart AH;Silverberg MS;;
Journal Journal of the Canadian Association of Gastroenterology
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/32328546/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32328546 pmc7165264 doi:10.1093/jcag/gwy065 petros zezos boyko kabakchiev mark s silverberg

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.